First Stargardt Patient Receives Vision‑Restoring Chip as Firm Sets Sights on Brain‑Computer Links

Science Corporation reported that its experimental vision‑restoring chip has been implanted for the first time in a human, a patient suffering from Stargardt disease.

Stargardt disease, a hereditary type of macular degeneration, gradually destroys central vision and can result in legal blindness. At present, treatment is confined to low‑vision devices, creating a significant demand for sight‑restoring therapies.

Created within the firm’s PRIMA program, the implant translates images recorded by a tiny camera into electrical pulses that activate surviving retinal cells, enabling the brain to perceive visual input. Though still early‑stage, the operation shows the system can be surgically installed and switched on without immediate adverse events.

At the recent TechCrunch Disrupt conference, Max Hodak—who previously served as president and co‑founder of Neuralink— described the retinal implant as a proof‑of‑concept for the company’s larger brain‑computer interface (BCI) strategy. He emphasized that perfecting the connection between external hardware and ocular neural tissue may guide later attempts to attach computers directly to other brain areas.

Both ophthalmology and neurotechnology circles are monitoring the procedure closely, seeing it as a promising route to regain functional sight for individuals with degenerative retinal disorders. Should future studies verify its safety and effectiveness, the method might be extended to treat age‑related macular degeneration and additional blindness types.

Science Corporation said it will start recruiting more subjects for a set of clinical trials designed to collect long‑term information on visual performance and device longevity. Although regulatory assessment and further validation remain prerequisites for commercial rollout, the successful inaugural surgery marks a concrete advance in merging vision restoration with brain‑computer interface technology.